公开(公告)号：US09114131B2

公开(公告)日：2015-08-25

申请号：US13877779

申请日：2011-10-04

申请人： Ichiro Watanabe ,  Yoshiharu Hiruma ,  Eisuke Tsuda ,  Tatsuji Matsuoka ,  Toshiaki Ohtsuka ,  Tohru Takahashi ,  Toshinori Agatsuma ,  Sandra Miller ,  Robert Mühlbacher ,  Kathrin-Ladetzki Baehs ,  Steffen Runz ,  Ulrike Schubert ,  Ingrid Schuster ,  Dirk Ponsel

发明人： Ichiro Watanabe ,  Yoshiharu Hiruma ,  Eisuke Tsuda ,  Tatsuji Matsuoka ,  Toshiaki Ohtsuka ,  Tohru Takahashi ,  Toshinori Agatsuma ,  Sandra Miller ,  Robert Mühlbacher ,  Kathrin-Ladetzki Baehs ,  Steffen Runz ,  Ulrike Schubert ,  Ingrid Schuster ,  Dirk Ponsel

IPC分类号： A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/22 ,  C12N5/10 ,  C12N15/11 ,  C12N15/63 ,  C07K16/28 ,  A61K45/06

CPC分类号： A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/92

摘要： An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

摘要翻译： 能够结合抑制破骨细胞形成和/或破骨细胞骨吸收的Siglec-15的分离抗体或其功能片段。 抗体的重链包含CDRH1，其包含与SEQ ID NO：106具有至少80％序列同一性的序列，CDRH2包含与SEQ ID NO：107具有至少80％序列同一性的序列，以及CDRH3，其包含 具有与SEQ ID NO：35,45,55,65或80之一具有至少80％序列同一性的序列。抗体的轻链包含CDRL1，其包含与SEQ ID NO：73具有至少80％序列同一性的序列 或83，CDRL2，其包含与SEQ ID NO：108具有至少80％序列同一性的序列，和CDRL3，其包含与SEQ ID NO：40,50,60,70， 90，100或109。

公开(公告)号：US20130280276A1

公开(公告)日：2013-10-24

申请号：US13877779

申请日：2011-10-04

申请人： Ichiro Watanabe ,  Yoshiharu Hiruma ,  Eisuke Tsuda ,  Tatsuji Matsuoka ,  Toshiaki Ohtsuka ,  Tohru Takahashi ,  Toshinori Agatsuma ,  Sandra Miller ,  Robert Mühlbacher ,  Kathrin-Ladetzki Baehs ,  Steffen Runz ,  Ulrike Schubert ,  Ingrid Schuster ,  Dirk Ponsel

发明人： Ichiro Watanabe ,  Yoshiharu Hiruma ,  Eisuke Tsuda ,  Tatsuji Matsuoka ,  Toshiaki Ohtsuka ,  Tohru Takahashi ,  Toshinori Agatsuma ,  Sandra Miller ,  Robert Mühlbacher ,  Kathrin-Ladetzki Baehs ,  Steffen Runz ,  Ulrike Schubert ,  Ingrid Schuster ,  Dirk Ponsel

IPC分类号： A61K39/395 ,  A61K45/06

CPC分类号： A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/92

摘要： An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

摘要翻译： 能够结合抑制破骨细胞形成和/或破骨细胞骨吸收的Siglec-15的分离抗体或其功能片段。 抗体的重链包含CDRH1，其包含与SEQ ID NO：106具有至少80％序列同一性的序列，CDRH2包含与SEQ ID NO：107具有至少80％序列同一性的序列，以及CDRH3，其包含 具有与SEQ ID NO：35,45,55,65或80之一具有至少80％序列同一性的序列。抗体的轻链包含CDRL1，其包含与SEQ ID NO：73具有至少80％序列同一性的序列 或83，CDRL2，其包含与SEQ ID NO：108具有至少80％序列同一性的序列，和CDRL3，其包含与SEQ ID NO：40,50,60,70， 90，100或109。